|
1
|
Vergne Y, Matta J, Morales L, Vargas W,
Alvarez-Garriga C and Bayona M: Breast cancer and dna repair
capacity: Association with use of multivitamin and calcium
supplements. Integr Med (Encinitas). 12:38–46. 2013.PubMed/NCBI
|
|
2
|
Wolmark N, Mamounas EP, Baehner FL, Butler
SM, Tang G, Jamshidian F, Sing AP, Shak S and Paik S: Prognostic
impact of the combination of recurrence score and quantitative
Estrogen Receptor Expression (ESR1) on predicting late distant
recurrence risk in estrogen receptor-positive breast cancer after 5
years of tamoxifen: results from NRG Oncology/National surgical
adjuvant breast and bowel project B-28 and B-14. J Clin Oncol.
34:2350–2358. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ingle JN: Postmenopausal women with
hormone receptor-positive breast cancer: Balancing benefit and
toxicity from aromatase inhibitors. Breast. 22 Suppl 2:S180–S183.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Manavalan TT, Teng Y, Appana SN, Datta S,
Kalbfleisch TS, Li Y and Klinge CM: Differential expression of
microRNA expression in tamoxifen-sensitive MCF-7 versus
tamoxifen-resistant LY2 human breast cancer cells. Cancer Lett.
313:26–43. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Early Breast Cancer Trialists'
Collaborative Group (EBCTCG), . Davies C, Godwin J, Gray R, Clarke
M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, et al: Relevance
of breast cancer hormone receptors and other factors to the
efficacy of adjuvant tamoxifen: Patient-level meta-analysis of
randomised trials. Lancet. 378:771–784. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Early Breast Cancer Trialists'
Collaborative Group (EBCTCG), . Effects of chemotherapy and
hormonal therapy for early breast cancer on recurrence and 15-year
survival: An overview of the randomised trials. Lancet.
365:1687–1717. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gutierrez MC, Detre S, Johnston S, Mohsin
SK, Shou J, Allred DC, Schiff R, Osborne CK and Dowsett M:
Molecular changes in tamoxifen-resistant breast cancer:
Relationship between estrogen receptor, HER-2, and p38
mitogen-activated protein kinase. J Clin Oncol. 23:2469–2476. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cui Y, Zhang M, Pestell R, Curran EM,
Welshons WV and Fuqua SA: Phosphorylation of estrogen receptor
alpha blocks its acetylation and regulates estrogen sensitivity.
Cancer Res. 64:9199–9208. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim VN, Han J and Siomi MC: Biogenesis of
small RNAs in animals. Nat Rev Mol Cell Biol. 10:126–139. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Valencia-Sanchez MA, Liu J, Hannon GJ and
Parker R: Control of translation and mRNA degradation by miRNAs and
siRNAs. Genes Dev. 20:515–524. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Calin GA and Croce CM: Chromosomal
rearrangements and microRNAs: A new cancer link with clinical
implications. J Clin Invest. 117:2059–2066. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: Diagnostics, monitoring and therapeutics.
A comprehensive review. EMBO Mol Med. 9:8522017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Iorio MV, Ferracin M, Liu CG, Veronese A,
Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M,
et al: MicroRNA gene expression deregulation in human breast
cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Volinia S, Galasso M, Sana ME, Wise TF,
Palatini J, Huebner K and Croce CM: Breast cancer signatures for
invasiveness and prognosis defined by deep sequencing of microRNA.
Proc Natl Acad Sci USA. 109:3024–3029. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu X, Luo A, Liu Y, Wang S, Li Y, Shi W,
Liu Z and Qu X: MiR-214 increases the sensitivity of breast cancer
cells to tamoxifen and fulvestrant through inhibition of autophagy.
Mol Cancer. 14:2082015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shen R, Wang Y, Wang CX, Yin M, Liu HL,
Chen JP, Han JQ and Wang WB: MiRNA-155 mediates TAM resistance by
modulating SOCS6-STAT3 signalling pathway in breast cancer. Am J
Transl Res. 15:2115–2126. 2015.
|
|
18
|
Cittelly DM, Das PM, Spoelstra NS,
Edgerton SM, Richer JK, Thor AD and Jones FE: Downregulation of
miR-342 is associated with tamoxifen resistant breast tumors. Mol
Cancer. 9:3172010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ikeda K, Horie-Inoue K, Ueno T, Suzuki T,
Sato W, Shigekawa T, Osaki A, Saeki T, Berezikov E, Mano H and
Inoue S: miR-378a-3p modulates tamoxifen sensitivity in breast
cancer MCF-7 cells through targeting GOLT1A. Sci Rep. 5:131702015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ward A, Shukla K, Balwierz A, Soons Z,
König R, Sahin O and Wiemann S: MicroRNA-519a is a novel oncomir
conferring tamoxifen resistance by targeting a network of
tumour-suppressor genes in ER+ breast cancer. J Pathol.
233:368–379. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Johnston SR and Yeo B: The optimal
duration of adjuvant endocrine therapy for early stage breast
cancer-with what drugs and for how long? Curr Oncol Rep.
16:3582014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Williams N and Harris LN: The renaissance
of endocrine therapy in breast cancer. Curr Opin Obstet Gynecol.
26:41–47. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cai H, An Y, Chen X, Sun D, Chen T, Peng
Y, Zhu F, Jiang Y and He X: Epigenetic inhibition of miR-663b by
long non-coding RNA HOTAIR promotes pancreatic cancer cell
proliferation via up-regulation of insulin-like growth factor 2.
Oncotarget. 7:86857–86870. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Du M, Shi D, Yuan L, Li P, Chu H, Qin C,
Yin C, Zhang Z and Wang M: Circulating miR-497 and miR-663b in
plasma are potential novel biomarkers for bladder cancer. Sci Rep.
5:104372015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao H, Li M, Li L, Yang X, Lan G and
Zhang Y: MiR-133b is down-regulated in human osteosarcoma and
inhibits osteosarcoma cells proliferation, migration and invasion,
and promotes apoptosis. PLoS One. 8:e835712013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang YL, Shen Y, Xu JP, Han K, Zhou Y,
Yang S, Yin JY, Min DL and Hu HY: Pterostilbene suppresses human
endometrial cancer cells in vitro by down-regulating miR-663b. Acta
Pharmacol Sin. 38:1394–1400. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liang S, Zhang N, Deng Y, Chen L, Zhang Y,
Zheng Z, Luo W, Lv Z, Li S and Xu T: miR-663b promotes tumor cell
proliferation, migration and invasion in nasopharyngeal carcinoma
through targeting TUSC2. Exp Ther Med. 14:1095–1103. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Casciano I, Mazzocco K, Boni L, Pagnan G,
Banelli B, Allemanni G, Ponzoni M, Tonini GP and Romani M:
Expression of DeltaNp73 is a molecular marker for adverse outcome
in neuroblastoma patients. Cell Death Differ. 9:246–251. 2002.
View Article : Google Scholar : PubMed/NCBI
|
